Altermune Technologies LLC was founded with the mission to develop novel therapeutics aimed at combating resistant pathogens such as MRSA, C. difficile, pseudomonas, and pandemic influenza. The company leverages a team of in-house scientists and a broad network of partnerships, including collaborative research arrangements with universities in the USA and Europe, as well as corporate relationships with companies specializing in oligonucleotide synthesis and aptamer selection. Their market focus is on addressing global health challenges posed by antibiotic-resistant bacteria and viral infections.

Notable affiliated individuals include a team of experienced scientists and researchers, though specific names are not provided. Altermune Technologies has established significant collaborations with academic institutions and industry partners, enhancing its research capabilities and innovation potential. The company's impact lies in its contribution to the development of advanced therapeutics that target some of the most challenging and resistant pathogens, aiming to improve global health outcomes.